Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$48.26 - $78.59 $238,887 - $389,020
4,950 Added 27.56%
22,911 $1.56 Million
Q1 2023

May 12, 2023

SELL
$46.97 - $58.27 $46,312 - $57,454
-986 Reduced 5.2%
17,961 $870,000
Q4 2022

Feb 14, 2023

SELL
$52.05 - $65.0 $1.09 Million - $1.36 Million
-20,932 Reduced 52.49%
18,947 $0
Q3 2022

Nov 04, 2022

SELL
$25.16 - $60.63 $251 - $606
-10 Reduced 0.03%
39,879 $2.42 Million
Q2 2022

Aug 15, 2022

SELL
$22.73 - $39.98 $736,906 - $1.3 Million
-32,420 Reduced 44.84%
39,889 $1.08 Million
Q1 2022

May 13, 2022

SELL
$30.27 - $49.22 $128,950 - $209,677
-4,260 Reduced 5.56%
72,309 $2.65 Million
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $2.86 Million - $4.97 Million
-67,880 Reduced 46.99%
76,569 $3.78 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $4.21 Million - $6.88 Million
87,270 Added 152.63%
144,449 $10.3 Million
Q2 2021

Aug 16, 2021

SELL
$21.63 - $57.65 $342,078 - $911,734
-15,815 Reduced 21.67%
57,179 $2.94 Million
Q1 2021

May 12, 2021

SELL
$11.0 - $28.24 $48,444 - $124,368
-4,404 Reduced 5.69%
72,994 $1.83 Million
Q4 2020

Feb 16, 2021

BUY
$10.12 - $13.94 $61,731 - $85,034
6,100 Added 8.56%
77,398 $929,000
Q3 2020

Nov 16, 2020

SELL
$9.93 - $13.47 $116,151 - $157,558
-11,697 Reduced 14.09%
71,298 $712,000
Q2 2020

Aug 12, 2020

BUY
$9.56 - $12.51 $31,012 - $40,582
3,244 Added 4.07%
82,995 $868,000
Q1 2020

May 12, 2020

BUY
$7.54 - $15.77 $1,802 - $3,769
239 Added 0.3%
79,751 $853,000
Q4 2019

Feb 11, 2020

BUY
$7.48 - $17.01 $8,527 - $19,391
1,140 Added 1.45%
79,512 $1.26 Million
Q3 2019

Nov 13, 2019

BUY
$6.89 - $10.45 $469,222 - $711,665
68,102 Added 663.12%
78,372 $614,000
Q2 2019

Aug 08, 2019

BUY
$8.85 - $12.49 $90,889 - $128,272
10,270 New
10,270 $0

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $668M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.